Dengue is one of the diseases that most presented variants in Brazil. Including, several people have already contracted the virus and suffered the consequences. Every year, especially in the summer, this is one of the biggest concerns of citizens, as it is exactly at this time that more cases of dengue appear. A vaccine that can give people security has been researched so that the risks can be mitigated.
Read more: Vaccine against Covid-19: fifth dose has already started to be applied in Brazil
see more
How to get your CNH for free in 2023?
After hacker attacks, Microsoft releases free tools for…
The vaccine developed by the Butantan Institute to combat dengue reached about 79.6% of proven efficacy and brought relief to many. The team that has been monitoring the evolution of clinical tests for two years, proved that 16,000 test participants did not register any aggravating factor in the disease.
Research by the Butantan Institute
The study pointed out that immunization was evaluated almost a month after the application was made and continued to be analyzed for two years. Clinical trials of the dengue vaccine began in 2016. The immunizer was applied to about 10,000 volunteers, all aged between 2 and 59 years old.
In addition to these volunteers, more than 6,000 received the placebo dose.
According to the researchers, the effectiveness showed a greater strength in people who had had dengue before the study began. The number reached 89.2%. For people who had never contracted it, the result was 73.5%.
When the research began, only two serotypes of dengue were circulating in Brazil, but the effectiveness in question extends to the other variations. The expected date for the end of the study is scheduled for 2024, accounting for a total of about five years of clinical studies. The percentage to avoid variants are 89.5% and 69.6%, for those who have already contracted the disease and for those who have not yet contracted it.
What are the effects of the vaccine?
Between 2010 and 2012, the first phase of clinical testing began in the United States, but it was only in the second part that research began to be carried out in Brazil. Against dengue, Butantan's vaccine makes use of technology from the US National Institute of Health.
The effects of the vaccine are not scary. For every 10,000 people immunized, only three had different effects when receiving the dose. Despite the side effect, all managed to recover.
Lover of movies and series and everything that involves cinema. An active curious on the networks, always connected to information about the web.
